Fig. 4
Baseline mutation landscape in RET-fusion positive NSCLC patients. NSCLC non-small-cell lung cancer, PD progressive disease, PFS progression-free survival, PR partial response, RET rearranged during transfection, SD stable disease
Fig. 4 | Signal Transduction and Targeted Therapy
